Press Releases:

17 March 2017 Global Venture Firm NEA Joins SetPoint Medical Syndicate of Investors

4 January 2017 SetPoint Medical Presents Positive Results In Ongoing Crohn’s Disease Study

19 October 2016 SetPoint Medical Presents Positive Clinical Results in Crohn’s Disease

21 September 2016 SetPoint Medical’s Progress Fuels Corporate Headquarters Relocation

12 September 2016 SetPoint Medical Expands Management Team to Support Advancement of Bioelectronic Medicine Platform

4 July 2016 Breakthrough First-in-Human Study Shows Vagus Nerve Stimulation Significantly Reduces Rheumatoid Arthritis Symptoms, Inhibits Cytokine Production

8 September 2015: SetPoint Announces $15 Million Equity Financing, Adds Major Strategic Investor

4 December 2014: SetPoint Announces First Trial of Bioelectronic Therapy to Treat Crohn's Disease

15 October 2013: SetPoint Medical Named One of the "Fierce 15" Leading Medical Technology Companies of 2013

8 August 2013: GSK launches $50 million venture capital fund to invest in pioneering bioelectronic medicines and technologies

8 August 2013: SetPoint Medical Secures $27 Million Financing, Adding Action Potential Venture Capital/GSK, Boston Scientific and Covidien Ventures as New Investors

7 August 2013: GSK switches on to electonic medicine


Media Coverage:

23 January 2017 10 Medical Advances that Are Giving Us Hope in 2017 and Beyond

22 September 2016: Could an electronic implant switch off rheumatoid arthritis?

8 July 2016: The Wall Street Journal - The Future of Bioelectronic Medicine

4 July 2016: Vagus nerve stimulation inhibits cytokine production and attenuates disease severity in rheumatoid arthritis

23 May 2014: The New York Times - Can the Nervous System Be Hacked?

13 February 2014: The World’s Top 10 Most Innovative Companies In Health Care

4 November 2013: Funding Dries Up for Medical Startups

7 August 2013: GSK switches on to electonic medicine

S5 Box




Fields marked with an asterisk (*) are required.